Arch Biopartners Inc V.ARCH

PONTIAC Cilastatin market update?

[Cb27743]

The PONTIAC clinical team sponsoring the trial is based in Calgary and is currently preparing to submit a Clinical Trial Application (CTA) to Health Canada to proceed with the trial by the fourth quarter of 2024. Arch is acting as a study partner for grant funding opportunities, providing cilastatin drug product and providing scientific and regulatory advice.

[Viking2233]

Welll I doubt that date is achievable and quite frankly this trial is not controlled by Arch. I think Arch's current AKi trial that involves three Canadian sites should serve as a guideline and reminder to investors that obtaining the required approvals is a very lengthy approval process. Arch is simply providing the drug and we have zero communication from either Arch or the group